Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma

Speaking of SurgOnc

المحتوى المقدم من Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

3+ y ago 12:51

MP3•منزل الحلقة

Rick Greene, MD, and Melissa Hogg, MD, discuss the relationship of serum CA19-9 to other markers of response, and the related thresholds correlating to outcomes, following neoadjuvant therapy for pancreatic adenocarcinoma. Dr. Hogg is author of the article, “Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.”

Dr. Hogg is the Director of HPB Surgery and Director of Robotic Training for Grainger Lab at the Northshore University Healthsystem, Chicago, IL.

59 حلقات

#Science #Annals of Surgical Oncology and Society of Surgical Oncology #Research #Globalcancersurgery #Surgicaloncology #Annals Of Surgical Oncology #Society Of Surgical Oncology #Podcasting Education